… Osimertinib was offered as second- and third-line treatment in 69.6 and … 1L therapy used,
due to its increased efficacy compared with the first-generation EGFR-TKIs erlotinib and gefitinib…

… from 9% (gefitinib 500-mg daily dose) to 12% (gefitinib 250-mg … Gefitinib was voluntarily
withdrawn from the US market in … 11.9 months in the erlotinib group compared with 9.6 months in …

… We aimed to collect real-world data regarding the efficacy … lazertinib as a second- or third-line
therapy. The ORR and DCR … However, our results demonstrate no significant difference …

… control than erlotinib monotherapy in patients with advanced … and dacomitinib had remarkable
efficacy compared to first-… subsequent second- and third-line therapy was not different …

… In the progression after EGFR-TKI, in the second-line treatment, the efficacy of osimertinib
was … second and third-line regimens in an EGFR-wild patient group compared erlotinib with …

… study (NCT02998528) compared the efficacy of neoadjuvant … patients compared with
comparator EGFR-TKI (gefitinib or erlotinib) … For the third-line therapy of NSCLC, anlotinib has …

… - or third-line therapy for advanced non-small-cell lung cancer revealed favorable tolerability.
However, the efficacy … , compared to pemetrexed and cisplatin alone in patients with locally …

… -line chemotherapy; no other second- or third-line treatments … one received ectinib, erlotinib,
and gefitinib, respectively. … with advanced NSCLC in the real world, we compared the clinical …

… gene mutation, compared with erlotinib alone. Subsequently, … a third-line monotherapy for
advanced gastric cancer patients, … Combined with PK analysis, safety, and efficacy profile, our …

… controlled trials (RCTs) comparing EGFR-TKIs with and without … A clinical study 12 compared
erlotinib combined with or … alone in second- and third-line treatment due to the blocking of …